Gynecologic Cancer News

The FDA granted fast track designation to TRQ-1501, a deep-primed IL-15 T-cell immunotherapy for the treatment of relapsed or refractory solid tumors and lymphomas that express any of five tumor-associated antigens, according to the agent’s manufacturer.

CHICAGO — Patients with anti-PD-1-naive triple-negative breast cancer and PD-1-relapsed or refractory melanoma demonstrated antitumor benefit from MIW815 plus spartalizumab, according to results of a phase 1b study presented at ASCO Annual Meeting.

The addition of radiation to platinum-based chemotherapy did not improve RFS among women with stage III or IVA endometrial cancer, according to results of a randomized phase 3 study published in The New England Journal of Medicine.

CHICAGO — More than 70% of female gynecologic oncologists reported encountering sexual harassment during training or in practice, according to survey results presented at ASCO Annual Meeting.

CHICAGO — Women who underwent minimally invasive surgery for early-stage cervical cancer demonstrated higher odds of recurrence than women who underwent open surgery, according to results of a multicenter retrospective study presented at ASCO Annual Meeting.

CHICAGO — Olaparib monotherapy significantly improved overall response rates and PFS, with no new safety signals, compared with nonplatinum chemotherapy among women with germline BRCA-mutated, platinum-sensitive relapsed ovarian cancer, according to results of the randomized phase 3 SOLO3 study presented at ASCO Annual Meeting.

CHICAGO — Women with ovarian cancer appeared more likely to be diagnosed at an early stage and receive treatment within 30 days of diagnosis following implementation of the Affordable Care Act in 2010, according to results of a retrospective analysis presented at ASCO Annual Meeting.

CHICAGO — An alternative dosing strategy of pembrolizumab and nivolumab may substantially reduce pharmaceutical costs without compromising efficacy in treating various cancers, according to results of a retrospective study presented at ASCO Annual Meeting.

CHICAGO — Data from two trials evaluating the safety and efficacy of adoptive cell transfer with autologous tumor-infiltrating lymphocytes showed promising overall response rates for the treatment of advanced metastatic melanoma and cervical cancer, according to results presented at ASCO Annual Meeting.

CHICAGO — Proton chemoradiotherapy significantly reduced incidence of adverse events associated with unplanned hospitalizations compared with traditional photon chemoradiotherapy among adults with nonmetastatic cancers, according to results of a comparative effectiveness study presented at ASCO Annual Meeting.